IL-6-positive classical Hodgkin's lymphoma co-occurring with plasma cell type of Castleman's disease: Report of a case

International Journal of Hematology

Volumn 97, Issue 2, 2013, Pages 275-279

  Momoi, Akihito ^a   Kojima, Masaru ^b   Sakai, Takeshi ^a   Ajiro, Junya ^a   Isahai, Noriatsu ^a   Nagai, Kouichi ^a   Aoki, Sadao ^c  

^a Niigata Prefectural Central Hospital   (Japan)

^b DOKKYO MEDICAL UNIVERSITY   (Japan)

^c NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SCIENCES   (Japan)

Author keywords

Castleman's disease; Hodgkin's lymphoma; IL 6; Plasma cell type; Tocilizumab

Indexed keywords

ANTIGEN; BOB 1 CELL; CD15 ANTIGEN; CD20 ANTIGEN; CD246 ANTIGEN; CD3 ANTIGEN; CD30 ANTIGEN; CD45RB ANTIGEN; CYCLOPHOSPHAMIDE; INTERLEUKIN 6; METHOTREXATE; OCT 2 CELL; PREDNISOLONE; TOCILIZUMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ADULT; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; AXILLARY LYMPH NODE; BLOOD LEVEL; CASE REPORT; CLASSICAL HODGKIN LYMPHOMA; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; ENDOTHELIUM CELL; EOSINOPHIL; EPSTEIN BARR VIRUS; GERMINAL CENTER; HISTIOCYTE; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY CELL; LYMPH FOLLICLE; LYMPH NODE BIOPSY; LYMPHOCYTE; MALE; MEDIASTINUM MASS; MICROSCOPY; NODULAR SCLEROSIS HODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PLASMA CELL; PLEURA EFFUSION; REED STERNBERG CELL; SALVAGE THERAPY; BIOPSY; BLOOD; HODGKIN DISEASE; LYMPH NODE; METABOLISM; PATHOLOGY;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; GIANT LYMPH NODE HYPERPLASIA; HODGKIN DISEASE; HUMANS; INTERLEUKIN-6; LYMPH NODES; MALE; PLASMA CELLS;

EID: 84887605267     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-013-1262-7     Document Type: Article

References (17)

1. Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer. 1956;9: 822-30.
2. Larroche C, Cacoub P, Soulier J, Oksenhendler E, Clauvel JP, Piette JC, et al. Castleman's disease and lymphoma: report of eight cases in HIV-negative patients and literature review. Am J Hematol. 2002;69:119-26.
3. Kojima M, Nakamura S, Nishikawa M, Itoh H, Miyawaki S, Masawa N. Idiopathic multicentric Castlemans disease. A clinicopathologic and immunohistochemical study of five cases. Pathol Res Pract. 2005;201:325-32.
4. Maheswaran PR, Ramsay AD, Norton AJ, Roche WR. Hodgkin's disease presenting with the histological features of Castleman's disease. Histopathology. 1991;18:249-53.
5. Zarate-Osorno A, Medeiros LJ, Danon AD, Neiman RS. Hodgkin's disease with coexistent Castleman-like histologic features. A report of three cases. Arch Pathol Lab Med. 1994;118:270-4.
6. Abdel-Reheim FA, Koss W, Rappaport ES, Arber DA. Coexistence of Hodgkin's disease and giant lymph node hyperplasia of the plasma-cell type (Castleman's disease). Arch Pathol Lab Med. 1996;120:91-6.
7. Drut R, Larregina A. Angiofollicular lymph node transformation in Hodgkin's lymphoma. Pediatr Pathol. 1991;11:903-8.
8. Haque S, van Kirk R. Three patients with both Hodgkin' lymphoma and Castleman's disease: clinicopathologic correlations and lack of association with HHV-8. Indian J Med Paediatr Oncol. 2009;30:76-9.
9. McAloon EJ. Hodgkin's disease in a patient with Castleman's disease. N Engl J Med. 1985;313:758.
10. Molinie V, Diebold J, Perie G. Hodgkin's disease associated with localized or multicentric Castleman's disease. Arch Pathol Lab Med. 1995;119:201.
11. Saletti P, Ghielmini M, Scali G, Pedrinis E, Gueneau M, Cavalli F. Hodgkin's and Castleman's disease in a patient with systemic mastocytosis. Ann Hematol. 1999;78:97-100.
12. Doggett RS, Colby TV, Dorfman RF. Interfollicular Hodgkin's disease. Am J Surg Pathol. 1983;7:145-9.
13. Hsu SM, Xie SS, Hsu PL, Waldron JA Jr. Interleukin-6, but not interleukin-4, is expressed by Reed-Sternberg cells in Hodgkin's disease with or without histologic features of Castleman's disease. Am J Pathol. 1992;141:129-38.
14. Zhou L, Ivanov II, Spolski R, Min R, Shenderov K, Eqawa T, et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol. 2007;8:967-74.
15. Kurzrock R, Redman J, Cabanillas F, Jones D, Rothberg J, Talpaz M. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms. Cancer Res. 1993;53:2118-22.
16. Gaiolla RD, Domingues MA, Niero-Melo L, de Oliveira DE. Serum levels of interleukins 6, 10, and 13 before and after treatment of classic Hodgkin lymphoma. Arch Pathol Lab Med. 2011;135:483-9.
17. Casasnovas RO, Mounier N, Brice P, Divine M, Morschhauser F, Gabarre J, et al. Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: A study from the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2007;25:1732-40.